Immunovant’s thyroid eye disease treatment shows positive phase 2a results

IMVT-1401, a thyroid eye disease treatment candidate, showed a 65% improvement in IgG levels in a phase 2a proof-of-concept study, Immunovant announced in a press release.

The multicenter, open-label, single-arm ASCEND GO-1 clinical trial included seven adult patients who received two weekly 680 mg subcutaneous doses of IMVT-1401 followed by four weekly 340 mg subcutaneous doses, the release said.

Four of the seven patients had an improvement of 2 points or more in clinical activity score. Six of the seven participants had baseline diplopia, and four of them experienced improvement.

“These results provide an early proof of concept of the potential for IMVT-1401 to ultimately become a safe and effective treatment for patients suffering from thyroid eye disease,” Pete Salzmann, MD, CEO of Immunovant, said in the release. “Importantly, IMVT-1401 was delivered by subcutaneous injection, opening the possibility of at-home treatment rather than infusion center-based treatment for patients with thyroid eye disease. We look forward to reporting the study’s full results, including detailed lab observations and 12 weeks of follow-up data, at an upcoming medical meeting.”

IMVT-1401, a thyroid eye disease treatment candidate, showed a 65% improvement in IgG levels in a phase 2a proof-of-concept study, Immunovant announced in a press release.

The multicenter, open-label, single-arm ASCEND GO-1 clinical trial included seven adult patients who received two weekly 680 mg subcutaneous doses of IMVT-1401 followed by four weekly 340 mg subcutaneous doses, the release said.

Four of the seven patients had an improvement of 2 points or more in clinical activity score. Six of the seven participants had baseline diplopia, and four of them experienced improvement.

“These results provide an early proof of concept of the potential for IMVT-1401 to ultimately become a safe and effective treatment for patients suffering from thyroid eye disease,” Pete Salzmann, MD, CEO of Immunovant, said in the release. “Importantly, IMVT-1401 was delivered by subcutaneous injection, opening the possibility of at-home treatment rather than infusion center-based treatment for patients with thyroid eye disease. We look forward to reporting the study’s full results, including detailed lab observations and 12 weeks of follow-up data, at an upcoming medical meeting.”